Cas No.: | 2134602-45-0 |
Chemical Name: | 5,6-dichloro-1-(1-(4-chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one methanesulfonate |
Synonyms: | SR1 7018,SR-17018,SR17018 |
SMILES: | C1=CC(CN2CCC(N3C(=O)NC4C=C(Cl)C(Cl)=CC3=4)CC2)=CC=C1Cl |
Formula: | C19H18Cl3N3O |
M.Wt: | 410.72 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM. |
Target: | EC50: 97 nM (MOR)[1] |
In Vitro: | SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM. SR17018 shows no obvious effect on inducing βarrestin2 recruitment to the MOR at below 10 μM. SR17018 promotes signaling through G proteins or βarrestin2[1]. |
References: | [1]. Schmid CL, et al. Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. Cell. 2017 Nov 16;171(5):1165-1175.e13. |